Ulys LLC’s Lexicon Pharmaceuticals LXRX Stock Holding History

Ulys LLC’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$25.4M	Hold	4,321,214	–	–	100%	1
2020 Q4	$14.8M	Hold	4,321,214	–	–	100%	1
2020 Q3	$6.22M	Hold	4,321,214	–	–	100%	1
2020 Q2	$8.62M	Hold	4,321,214	–	–	100%	1
2020 Q1	$8.43M	Hold	4,321,214	–	–	100%	1
2019 Q4	$17.9M	Hold	4,321,214	–	–	100%	1
2019 Q3	$13M	Hold	4,321,214	–	–	100%	1
2019 Q2	$27.2M	Hold	4,321,214	–	–	100%	1
2019 Q1	$24M	Hold	4,321,214	–	–	100%	1
2018 Q4	$28.7M	Hold	4,321,214	–	–	100%	1
2018 Q3	$46.1M	Hold	4,321,214	–	–	100%	1
2018 Q2	$51.9M	Hold	4,321,214	–	–	100%	1
2018 Q1	$37M	Hold	4,321,214	–	–	100%	1
2017 Q4	$42.7M	Hold	4,321,214	–	–	100%	1
2017 Q3	$53.1M	Hold	4,321,214	–	–	100%	1
2017 Q2	$71.1M	Hold	4,321,214	–	–	100%	1
2017 Q1	$62M	Hold	4,321,214	–	–	100%	1
2016 Q4	$59.8M	Hold	4,321,214	–	–	100%	1
2016 Q3	$78.1M	Hold	4,321,214	–	–	100%	1
2016 Q2	$62M	Hold	4,321,214	–	–	100%	1
2016 Q1	$51.6M	Hold	4,321,214	–	–	100%	1
2015 Q4	$57.5M	Hold	4,321,214	–	–	100%	1
2015 Q3	$46.4M	Hold	4,321,214	–	–	99.99%	1
2015 Q2	$34.8M	Sell	4,321,214 -1	-0%	-$7	99.98%	1
2015 Q1	$28.4M	Hold	4,321,215	–	–	99.96%	1
2014 Q4	$27.5M	Buy	4,321,215 +66,557	+2%	+$537K	99.97%	1
2014 Q3	$42M	Hold	4,254,658	–	–	99.97%	1
2014 Q2	$48M	Hold	4,254,658	–	–	99.96%	1
2014 Q1	$51.5M	Hold	4,254,658	–	–	99.95%	1
2013 Q4	$53.6M	Hold	4,254,658	–	–	99.92%	1
2013 Q3	$70.9M	Hold	4,254,658	–	–	99.94%	1
2013 Q2	$64.6M	Buy	+4,254,658	New	+$64.7M	99.85%	1

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Ulys LLC's LXRX Position: Q1 2021 in Review

Ulys LLC held its Lexicon Pharmaceuticals (LXRX) position steady in Q1 2021 at 4,321,214 shares worth $25.4M. The position accounts for 100% of the portfolio, ranked #1.

Ulys LLC first reported a position in LXRX in Q2 2013 and has held it in 32 quarters since. The position peaked at $78.1M in Q3 2016. 107 funds tracked by Wall St. Rank hold LXRX as of Q1 2021.

Ulys LLC held 4,321,214 shares of Lexicon Pharmaceuticals worth $25.4M as of Q1 2021.
Ulys LLC left its Lexicon Pharmaceuticals share count unchanged in Q1 2021.
Lexicon Pharmaceuticals made up 100% of Ulys LLC's portfolio in Q1 2021, its #1 holding.
Ulys LLC first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 32 quarters since.
Ulys LLC's Lexicon Pharmaceuticals position peaked at $78.1M in Q3 2016.
107 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2021.

Based on Ulys LLC's 13F filing for Q1 2021, filed 14 May 2021.